F5 Inc vs Medtronic PLC — how do they compare? F5 Inc trades at $404.06 (market cap $23.79B), while Medtronic PLC trades at $84.48 (market cap $103.01B). The key difference: Medtronic PLC is far larger — about 4.3× F5 Inc's market cap, and Medtronic PLC pays a 3.58% dividend while F5 Inc pays none. Which is the better fit depends on your goals.
| FFIV | MDT | |
|---|---|---|
Market Cap | $23.79B | $103.01B |
Sector | Technology | Health |
52-Week High | $431.26 | $105.35 |
52-Week Low | $223.99 | $73.75 |
Enterprise Value | $22.60B | $121.75B |
Dividend Yield | — | 3.58% |
Signals from Pluang's Aura AI — not financial advice
F5 Networks (FFIV) trades at $419.00, down 2.84% on the day, but remains in a bullish technical trend above key support levels. The company demonstrates strong fundamental momentum with revenue growth to $3.09B in 2025 and consistent earnings beats, including a recent Q1 2026 EPS of $3.90 against a $3.46 expectation. Recent news highlights strategic expansion into AI security, including the acquisition of SurePath AI (GeekWire, 2026-06-26).
The outlook is supported by robust profitability and strategic positioning in application security, but elevated valuation multiples (P/E 34.61, P/S 7.6) and a high current price relative to the analyst consensus target of $397.00 present near-term valuation risk. The primary investment opportunity lies in the company's execution on its AI security platform growth, while risks include competitive pressures and the stock's premium pricing.
Medtronic (MDT) trades at $79.30, down 5.11% over 24 hours, with technical indicators showing bearish momentum. Fundamentally, the company reported strong earnings beats for three consecutive quarters and maintains solid profitability with a 13.2% net income margin. Recent news highlights the completion of the Scientia Vascular acquisition and bullish analyst coverage citing undervaluation and growth in cardiovascular and neuroscience segments.
The stock presents a compelling opportunity with a consensus price target of $97.50 representing 23% upside, supported by 58% analyst buy ratings. Key risks include increasing debt-to-asset ratios (31.11% in 2025) and margin pressures from tariffs and foreign exchange. The dividend aristocrat offers a near-decade high yield with consistent dividend growth.
Trailing returns across standard periods
Latest headlines on both assets
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →